Literature DB >> 21731418

Starting subcutaneous insulin doses in a paediatric population with newly diagnosed type 1 diabetes.

Lisa Lemieux1, Susan Crawford, Danièle Pacaud.   

Abstract

BACKGROUND: Starting subcutaneous insulin doses in children with newly diagnosed type 1 diabetes vary widely from 0.2 units/kg/day to 0.8 units/kg/day. AIM: To determine whether there are correlations between starting insulin dose and diabetes-related outcomes.
METHODS: By reviewing the charts of children newly diagnosed with type 1 diabetes, the prevalence of hypoglycemia in the first 48 h was compared between those who received low (0.5 units/kg/day or less) and those who received high (greater than 0.5 units/kg/day) starting insulin doses.
RESULTS: Forty-two children were initially prescribed a low dose of insulin, and 55 children were given a high dose. Approximately one-third of children (36.4%) younger than six years of age who received a high starting dose of insulin had mild hypoglycemia within 48 h of subcutaneous insulin initiation, compared with 16.0% of children six to 10 years of age and 5.3% of children older than 10 years of age.
CONCLUSIONS: Hypoglycemia was not more frequent among children given high-insulin starting doses. However, children younger than six years of age remained at increased risk for hypoglycemia.

Entities:  

Keywords:  Adolescents; Children; Insulin therapy; Type 1 diabetes

Year:  2010        PMID: 21731418      PMCID: PMC2921730          DOI: 10.1093/pch/15.6.357

Source DB:  PubMed          Journal:  Paediatr Child Health        ISSN: 1205-7088            Impact factor:   2.253


  14 in total

1.  Factors predicting residual beta-cell function in the first year after diagnosis of childhood type 1 diabetes.

Authors:  J J Couper; I Hudson; G A Werther; G L Warne; J M Court; L C Harrison
Journal:  Diabetes Res Clin Pract       Date:  1991-01       Impact factor: 5.602

Review 2.  Five stages of evolving beta-cell dysfunction during progression to diabetes.

Authors:  Gordon C Weir; Susan Bonner-Weir
Journal:  Diabetes       Date:  2004-12       Impact factor: 9.461

3.  The transient effect of strict glycaemic control on B cell function in newly diagnosed type 1 (insulin-dependent) diabetic patients.

Authors:  S Madsbad; T Krarup; O K Faber; C Binder; L Regeur
Journal:  Diabetologia       Date:  1982-01       Impact factor: 10.122

4.  Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group.

Authors: 
Journal:  Ann Intern Med       Date:  1998-04-01       Impact factor: 25.391

Review 5.  Individualizing insulin management. Three practical cases, rules for regimen adjustment.

Authors:  Walter A Stoller
Journal:  Postgrad Med       Date:  2002-05       Impact factor: 3.840

6.  Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial.

Authors:  Michael W Steffes; Shalamar Sibley; Melissa Jackson; William Thomas
Journal:  Diabetes Care       Date:  2003-03       Impact factor: 19.112

7.  Parameters associated with residual insulin secretion during the first year of disease in children and adolescents with Type 1 diabetes mellitus.

Authors:  R Bonfanti; E Bazzigaluppi; G Calori; M C Riva; M Viscardi; E Bognetti; F Meschi; E Bosi; G Chiumello; E Bonifacio
Journal:  Diabet Med       Date:  1998-10       Impact factor: 4.359

Review 8.  Routine hospital admission versus out-patient or home care in children at diagnosis of type 1 diabetes mellitus.

Authors:  C Clar; N Waugh; S Thomas
Journal:  Cochrane Database Syst Rev       Date:  2003

9.  An ambulatory stabilisation program for children with newly diagnosed type 1 diabetes.

Authors:  Shubha Srinivasan; Maria E Craig; Linda Beeney; Rachel Hayes; Nuala Harkin; Geoffrey R Ambler; Kim C Donaghue; Christopher T Cowell
Journal:  Med J Aust       Date:  2004-03-15       Impact factor: 7.738

10.  Insulin secretion in type 1 diabetes.

Authors:  Chynna Steele; William A Hagopian; Stephen Gitelman; Umesh Masharani; Melissa Cavaghan; Kristina I Rother; David Donaldson; David M Harlan; Jeffrey Bluestone; Kevan C Herold
Journal:  Diabetes       Date:  2004-02       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.